HIF1A overexpression
|
HER2 Negative Breast Cancer
|
HIF1A overexpression
|
HER2 Negative Breast Cancer
|
albumin-bound paclitaxel Sensitive: B - Late Trials
|
albumin-bound paclitaxel Sensitive: B - Late Trials
|
HIF1A overexpression
|
AML
|
HIF1A overexpression
|
AML
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
HIF1A overexpression
|
MDS
|
HIF1A overexpression
|
MDS
|
azacitidine Sensitive: C3 – Early Trials
|
azacitidine Sensitive: C3 – Early Trials
|
HIF1A overexpression
|
SCCHN
|
HIF1A overexpression
|
SCCHN
|
nimotuzumab Sensitive: C3 – Early Trials
|
nimotuzumab Sensitive: C3 – Early Trials
|
HIF1A overexpression
|
SCCHN
|
HIF1A overexpression
|
SCCHN
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
HIF1A overexpression
|
NSCLC
|
HIF1A overexpression
|
NSCLC
|
EGFR inhibitor Resistant: D – Preclinical
|
EGFR inhibitor Resistant: D – Preclinical
|
HIF1A overexpression
|
Ovarian Cancer
|
HIF1A overexpression
|
Ovarian Cancer
|
CB-839 Sensitive: D – Preclinical
|
CB-839 Sensitive: D – Preclinical
|
HIF1A overexpression
|
Ovarian Cancer
|
HIF1A overexpression
|
Ovarian Cancer
|
olaparib + CB-839 Sensitive: D – Preclinical
|
olaparib + CB-839 Sensitive: D – Preclinical
|
HIF1A overexpression
|
HCC
|
HIF1A overexpression
|
HCC
|
sorafenib Resistant: D – Preclinical
|
sorafenib Resistant: D – Preclinical
|
HIF1A overexpression
|
CRC
|
HIF1A overexpression
|
CRC
|
5-fluorouracil Resistant: D – Preclinical
|
5-fluorouracil Resistant: D – Preclinical
|